You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

oligonucleotide

Showing 1 - 25 of 330
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumor Trial in Seoul (TASO-001((TGF-ß2 targeting anti-sense oligonucleotide), Aldesleukin)

Recruiting
  • Solid Tumor
  • TASO-001((TGF-β2 targeting anti-sense oligonucleotide)
  • Aldesleukin
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Jan 31, 2023

Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Tumors Trial in Houston (BP1001-A (Liposomal Grb2 Antisense

Not yet recruiting
  • Solid Tumor, Adult
  • +5 more
  • BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)
  • BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
  • (no location specified)
Jun 7, 2022

Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) Trial in Augusta, Nashville, Houston

Recruiting
  • Mantle Cell Lymphoma
  • +9 more
  • L-Bcl-2 antisense oligonucleotide
  • Augusta, Georgia
  • +2 more
Nov 18, 2022

Pancreatic Ductal Adenocarcinoma Trial (OT-101, FOLFIRINOX)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • (no location specified)
Oct 5, 2023

HIV Positive Trial in Maseno, Nairobi (Pre-ART Oligonucleotide Assay (OLA))

Completed
Has Results
  • HIV Positive
  • Pre-ART Oligonucleotide Assay (OLA)
  • Maseno, Kenya
  • +1 more
Oct 18, 2021

Antisense Oligonucleotide for Spinal Muscular Atrophy

Recruiting
  • Spinal Muscular Atrophy
  • Beijing, Beijing, China
  • +2 more
Jan 11, 2022

Advanced Hepatocellular Carcinoma Trial in Singapore (MTL-CEBPA, Atezolizumab, Bevacizumab)

Recruiting
  • Advanced Hepatocellular Carcinoma
  • Singapore, Singapore
    National University Hospital
Oct 27, 2021

Advanced Solid Tumors Trial (WGI-0301)

Not yet recruiting
  • Advanced Solid Tumors
  • (no location specified)
Jul 11, 2022

Advanced Malignant Solid Tumor, Extracranial Solid Tumor, Metastatic Malignant Solid Tumor Trial in Palo Alto (Anti-OX40

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Anti-OX40 Antibody BMS 986178
  • TLR9 Agonist SD-101
  • Palo Alto, California
    Stanford Cancer Institute Palo Alto
Jun 13, 2022

Rheumatoid Arthritis Trial in Canada, United States (ISIS 104838)

Completed
  • Rheumatoid Arthritis
  • ISIS 104838
  • Birmingham, Alabama
  • +30 more
Dec 1, 2022

Prostate Cancer Trial in Ann Arbor, Detroit (ARRx, Enzalutamide)

Suspended
  • Prostate Cancer
  • Ann Arbor, Michigan
  • +1 more
Dec 17, 2021

Healthy Participants Trial in Toronto (IONIS FXI-LRx, Placebo)

Completed
  • Healthy Participants
  • IONIS FXI-LRx
  • Placebo
  • Toronto, Ontario, Canada
    BioPharma Services Inc.
Jan 13, 2022

Amyloidosis Trial in Boston (Inotersen)

Active, not recruiting
  • Amyloidosis
  • Boston, Massachusetts
    Brigham and Women's Hospital
Dec 3, 2020

Hepatitis B, Chronic Trial in Worldwide (GSK3228836, GSK3528869A, Control)

Recruiting
  • Hepatitis B, Chronic
  • Edegem, Belgium
  • +47 more
Jan 24, 2023

Retinitis Pigmentosa, Usher Syndrome Type 2 Trial in Canada, France, United States (RNA antisense oligonucleotide for

Terminated
Has Results
  • Retinitis Pigmentosa
  • Usher Syndrome Type 2
  • RNA antisense oligonucleotide for intravitreal injection
  • Boston, Massachusetts
  • +6 more
Dec 12, 2022

Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind Trial in Dallas, Madison, London (QR-421a, Sham-procedure)

Active, not recruiting
  • Retinitis Pigmentosa
  • +7 more
  • Dallas, Texas
  • +2 more
Apr 21, 2022

Hepatocellular Carcinoma, Liver Cancer Trial in Singapore, Taiwan, United Kingdom (MTL-CEBPA, Sorafenib 200mg)

Active, not recruiting
  • Hepatocellular Carcinoma
  • Liver Cancer
  • Singapore, Singapore
  • +10 more
Apr 4, 2022

Progressive Supranuclear Palsy (PSP) Trial in Worldwide (antisense oligonucleotide, )

Recruiting
  • Progressive Supranuclear Palsy (PSP)
  • antisense oligonucleotide
  • placebo
  • La Jolla, California
  • +11 more
Feb 23, 2022

Acute Myeloid Leukemia (AML) Trial in United States (BP1001 in combination with Ventoclax plus decitabine, BP1001 plus

Recruiting
  • Acute Myeloid Leukemia (AML)
  • BP1001 in combination with Ventoclax plus decitabine
  • BP1001 plus decitabine
  • Fairway, Kansas
  • +5 more
Jan 3, 2022

Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind Trial in Canada, France, United States (QR-421a, Sham-procedure (dose

Completed
  • Retinitis Pigmentosa
  • +7 more
  • QR-421a
  • Sham-procedure (dose cohort 1&2 only)
  • Boston, Massachusetts
  • +6 more
Apr 19, 2022

Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind Trial in Worldwide (Ultevursen, Sham-procedure)

Recruiting
  • Retinitis Pigmentosa
  • +7 more
  • San Diego, California
  • +14 more
Jul 29, 2022

Helicobacter Pylori Infection, Antibiotic Resistant Infection Trial (Dual-priming oligonucleotide-based multiplex polymerase

Not yet recruiting
  • Helicobacter Pylori Infection
  • Antibiotic Resistant Infection
  • Dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR)
  • (no location specified)
Jul 4, 2020

Dravet Syndrome Trial in United States (STK-001 - Single Ascending Doses, STK-001 - Multiple Ascending Doses)

Recruiting
  • Dravet Syndrome
  • STK-001 - Single Ascending Doses
  • STK-001 - Multiple Ascending Doses
  • San Francisco, California
  • +17 more
Feb 17, 2022

Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome Trial in Houston (BP1001, BP1001

Completed
  • Recurrent Adult Acute Myeloid Leukemia
  • +3 more
  • BP1001
  • BP1001 in combination with LDAC
  • Houston, Texas
    M. D. Anderson Cancer Center
May 26, 2020

Glioblastoma Multiforme, Glioblastoma Trial in United States (biological, procedure, drug)

Not yet recruiting
  • Glioblastoma Multiforme
  • Glioblastoma
  • IGV-001 Cell Immunotherapy
  • +3 more
  • Newark, Delaware
  • +22 more
Jun 24, 2022